Role of Serum Amyloid A as a Biomarker for Predicting the Severity and Prognosis of COVID-19.

Autor: Abbas AA; Laboratory Department, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia.; Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Egypt., Alghamdi A; Laboratory Department, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia., Mezghani S; Division of Pulmonology, Allergy, and Immunology, Department of Medicine, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia.; Pulmonology, Allergy, and Immunology Department, University of Medicine of Sousse, Tunisia., Ben Ayed M; Laboratory Department, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia.; Clinical Pathology Department, University of Medicine of Sfax, Tunisia., Alamori AM; Laboratory Department, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia., Alghamdi GA; Laboratory Department, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia., Bajhmom W; Internal Medicine Department of King Fahd General Hospital, MOH, Jeddah, Saudi Arabia., Wajeeh H; Laboratory Department, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia., Almutairi SS; Laboratory Department, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia., Radwan WM; Laboratory Department, King Fahd General Hospital, MOH, Jeddah, Saudi Arabia.; Clinical Pathology Department, Faculty of Medicine, Menoufia University, Egypt.
Jazyk: angličtina
Zdroj: Journal of immunology research [J Immunol Res] 2022 Nov 24; Vol. 2022, pp. 6336556. Date of Electronic Publication: 2022 Nov 24 (Print Publication: 2022).
DOI: 10.1155/2022/6336556
Abstrakt: Objective: To detect biomarkers that can be used to predict COVID-19 severity to identify patients with high probability of disease progression and poor prognosis.
Methods: Of the 102 patients with confirmed COVID-19 who were admitted to King Fahd General Hospital, Jeddah City, Saudi Arabia, from July 1, 2021 to August 5, 2021, 50 were included in this cross-sectional study to investigate the influence of serum amyloid A (SAA) on disease severity and survival outcomes of COVID-19 patients. Dynamic shifts in SAA, C-reactive protein (CRP), white blood cell (WBC), lymphocytes, neutrophils, biochemical markers, and disease progression were examined. At admission, and at three, five, and seven days after treatment, at least four data samples were collected from all patients, and they underwent clinical status assessments.
Results: Critically ill patients showed higher SAA and CRP levels and WBC and neutrophil counts and significantly lower lymphocyte and eosinophil counts compared to the moderately/severely ill patients, especially with regard to disease progression. Similarly, nonsurvivors had higher SAA levels than survivors. The moderately/severely ill patients and the survivors had significantly higher dynamic changes in SAA compared to the critically ill patients and nonsurvivors, respectively, with differences clearly noticed on the fifth and seventh day of treatment. ROC curve analysis revealed that the combination of SAA and CRP was valuable in evaluating the disease progression and prognosis of COVID-19 patients at different time points; however, a combination of SAA and lymphocyte counts was more sensitive for disease severity prediction on admission. The most sensitive parameters for predicting survival on admission were the combination of SAA/WBC and SAA/neutrophil count.
Conclusions: The study findings indicate that SAA can be used as a sensitive indicator to assess the degree of disease severity and survival outcomes of COVID-19 patients.
Competing Interests: The authors declare no competing financial interests.
(Copyright © 2022 Amal A. Abbas et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje